Evening I have absolutely no axe to grind as am out if here but trying to shed some light on whether the big trades at end of day were buys or sells if you look at the last Lombard Holdings RNS their figure was 82,075,696 shares and look at the 9m share which ends in 696. May be coincidence and I have not been counting shares but
Gazza,Absolutely nothing wrong with that and thanks for doing so. Another issue is if viral infection in the community falls back it will lengthen the time necessary to complete the larger phase trials as they will need to either do challenge studies which are very difficult to scale up to necessary numbers or do trials in likes of Brazil orcRussia etc.
Morning Gazza, You have to be extremely careful in trying to assign prospects of success for any of these Vax candidates as there are huge risks whatever the approach even the mRNA one of Moderna. As you can see many candidates who are keen to fund their development may ramp up the likelihood of success.
Sorry the last paragraph was not relevant here but crucial thing from one of previous RNSs is.
The MosaiQ COVID-19 Antibody Microarray was CE marked (certified to meet EU requirements) as of 01 May 2020 based on testing that demonstrated 100% sensitivity (ability to detect COVID-19 antibodies) and 99.8% specificity (ability to rule out the presence of COVID-19 antibodies).
Those figures are fantastically high re sensitivity and specificity so very low number of false negatives and false positives so a really accurate test.
No worries Dave.Not a science guy but worked in pharma a lot of years and have experience at selling/ marketing Viral based Vax and also Rapid point of care viral testing kits along with plenty of other therapeutic areas. Really good prospects here but just makes me laugh sometimes when people look at “ competitor” tests and worry they are going to take the market. Firstly the market is huge on all testing whether Antibody or Antigen,whether lab based or not,whether rapid point of care or not. Secondly they all have their benefits and USPs and will all find their levels. The huge partnership deals here are so important for external validation and how successful these tests will be dependent on specificity and sensitivity accuracy. From what I have seen so far about the Affimer technology they are very accurate and flexible and the validation is critical
Hi Dave, Certainly not doubting the potential possibility of a universal Coronavirus Vaccine in the future but all the current 100+ candidates such as the Oxford ChAd Vax will not do this. It was more to explain the difference between current Flu Vax which are based on predicting which antigenic field strains are likely to be in circulation and the universal one which stimulates a cell mediated and humoral response to cater for any flu strain. The issue with Covid 19 is the need to specifically target the S and if possible the N protein and not worry too much at this stage about any potential new strains. One further point which is interesting and made by Pascal Soriott that many of the current Covid 19 Vax May struggle to compete their trials simply due to lack of community infection. This works in ORPHs favour in being able to doing challenge studies in U.K.- the difficulty of course is in scaling up the numbers. ATB
Jimzi, In fairness ORPH do communicate a lot there should not need to be a need for particular BB expertise. However,some should be made aware that there are differences between flu virus,s and Covid 19. The idea of a universal flu Vax is one that will create an immune response to new antigenic strains that we may not predict with accuracy. The Covid 19 Vax will not be a universal one so no MERS/SARS and will be specific vs the Spike protein and possibly N protein and may or may not work if the virus mutates.
Morning Trek, Very nice listen.I have been here for a couple of years but been busy elsewhere so was aware of some of news but great for CF to put it into context. Yes exciting times here and great interest by big pharma and good to get a mention of not only Companys who I have worked for in the past but the one I work for now who has got a current deal here. ATB